Shenzhen S.E.
06:00:00 2024-05-07 pm EDT
5-day change
1st Jan Change
28.64
CNY
-1.55%
+3.99%
+28.83%
Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023
April 26, 2024 at 03:40 pm EDT
Jafron Biomedical Co.,Ltd. announced on 26 April 2024 the profit distribution proposal for 2023 as follows: Final Cash dividend/10 shares (tax included): CNY 4.00000000.
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 25
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
Apr. 03
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
Apr. 03
CI
Jafron Biomedical Co.,Ltd.'s Equity Buyback announced on July 17, 2023, has closed with 24,242,904 shares, representing 3% for CNY 500 million.
Apr. 02
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
Jan. 02
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Zhuhai Jianfu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 15 million in funding from Jafron Biomedical Co.,Ltd.
23-10-22
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
23-10-12
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-18
CI
Jafron Biomedical Co.,Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.
23-07-17
CI
Jafron Biomedical Co.,Ltd. authorizes a Buyback Plan.
23-07-16
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Jafron Biomedical Co.,Ltd. Approves Director Elections
23-04-24
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-30
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-27
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-25
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-13
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-04-11
CI
Jafron Biomedical Co.,Ltd.'s Equity Buyback announced on September 23, 2021, has expired.
22-03-12
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-26
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on September 23, 2021.
21-10-12
CI
Jafron Biomedical Co.,Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.
21-09-22
CI
Jafron Biomedical Co.,Ltd. initiates a Market Repurchase.
21-09-21
CI
Jafron Biomedical Co.,Ltd.'s Board intends to launch an Equity Buyback.
21-08-26
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
More about the company
Last Close Price
28.64
CNY
Average target price
30.94
CNY
Spread / Average Target
+8.05%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
JAFRON BIOMEDICAL CO.,LTD. 
